0.000
0.00 (0.00%)
| Harga / Pendapatan (P/E Ke hadapan) | 5.00 |
| Harga / Jualan (P/S) | 2.58 |
| Harga / Buku (P/B) | 3.23 |
| Margin Keuntungan | -9.34% |
| Margin Operasi (TTM) | -6.94% |
| EPS Cair (TTM) | -2.28 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 4.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 139.67% |
| Nisbah Semasa (MRQ) | 2.51 |
| Aliran Tunai Operasi (OCF TTM) | 399.00 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 364.50 M |
| Pulangan Atas Aset (ROA TTM) | -0.18% |
| Pulangan Atas Ekuiti (ROE TTM) | -11.19% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Menaik | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Menaik | Bercampur | |
| Stok | Catalent, Inc. | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 0.0 |
| Purata | 1.25 |
|
Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.50% |
| % Dimiliki oleh Institusi | 87.89% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |